192 related articles for article (PubMed ID: 33097612)
1. Phase Ib study of anti-CSF-1R antibody emactuzumab in combination with CD40 agonist selicrelumab in advanced solid tumor patients.
Machiels JP; Gomez-Roca C; Michot JM; Zamarin D; Mitchell T; Catala G; Eberst L; Jacob W; Jegg AM; Cannarile MA; Watson C; Babitzki G; Korski K; Klaman I; Teixeira P; Hoves S; Ries C; Meneses-Lorente G; Michielin F; Christen R; Rüttinger D; Weisser M; Delord JP; Cassier P
J Immunother Cancer; 2020 Oct; 8(2):. PubMed ID: 33097612
[TBL] [Abstract][Full Text] [Related]
2. Phase I study of emactuzumab single agent or in combination with paclitaxel in patients with advanced/metastatic solid tumors reveals depletion of immunosuppressive M2-like macrophages.
Gomez-Roca CA; Italiano A; Le Tourneau C; Cassier PA; Toulmonde M; D'Angelo SP; Campone M; Weber KL; Loirat D; Cannarile MA; Jegg AM; Ries C; Christen R; Meneses-Lorente G; Jacob W; Klaman I; Ooi CH; Watson C; Wonde K; Reis B; Michielin F; Rüttinger D; Delord JP; Blay JY
Ann Oncol; 2019 Aug; 30(8):1381-1392. PubMed ID: 31114846
[TBL] [Abstract][Full Text] [Related]
3. Anti-CSF-1R emactuzumab in combination with anti-PD-L1 atezolizumab in advanced solid tumor patients naïve or experienced for immune checkpoint blockade.
Gomez-Roca C; Cassier P; Zamarin D; Machiels JP; Perez Gracia JL; Stephen Hodi F; Taus A; Martinez Garcia M; Boni V; Eder JP; Hafez N; Sullivan R; Mcdermott D; Champiat S; Aspeslagh S; Terret C; Jegg AM; Jacob W; Cannarile MA; Ries C; Korski K; Michielin F; Christen R; Babitzki G; Watson C; Meneses-Lorente G; Weisser M; Rüttinger D; Delord JP; Marabelle A
J Immunother Cancer; 2022 May; 10(5):. PubMed ID: 35577503
[TBL] [Abstract][Full Text] [Related]
4. CSF1R inhibition with emactuzumab in locally advanced diffuse-type tenosynovial giant cell tumours of the soft tissue: a dose-escalation and dose-expansion phase 1 study.
Cassier PA; Italiano A; Gomez-Roca CA; Le Tourneau C; Toulmonde M; Cannarile MA; Ries C; Brillouet A; Müller C; Jegg AM; Bröske AM; Dembowski M; Bray-French K; Freilinger C; Meneses-Lorente G; Baehner M; Harding R; Ratnayake J; Abiraj K; Gass N; Noh K; Christen RD; Ukarma L; Bompas E; Delord JP; Blay JY; Rüttinger D
Lancet Oncol; 2015 Aug; 16(8):949-56. PubMed ID: 26179200
[TBL] [Abstract][Full Text] [Related]
5. Neoadjuvant Selicrelumab, an Agonist CD40 Antibody, Induces Changes in the Tumor Microenvironment in Patients with Resectable Pancreatic Cancer.
Byrne KT; Betts CB; Mick R; Sivagnanam S; Bajor DL; Laheru DA; Chiorean EG; O'Hara MH; Liudahl SM; Newcomb C; Alanio C; Ferreira AP; Park BS; Ohtani T; Huffman AP; Väyrynen SA; Dias Costa A; Kaiser JC; Lacroix AM; Redlinger C; Stern M; Nowak JA; Wherry EJ; Cheever MA; Wolpin BM; Furth EE; Jaffee EM; Coussens LM; Vonderheide RH
Clin Cancer Res; 2021 Aug; 27(16):4574-4586. PubMed ID: 34112709
[TBL] [Abstract][Full Text] [Related]
6. A phase Ib study of utomilumab (PF-05082566) in combination with mogamulizumab in patients with advanced solid tumors.
Cohen EEW; Pishvaian MJ; Shepard DR; Wang D; Weiss J; Johnson ML; Chung CH; Chen Y; Huang B; Davis CB; Toffalorio F; Thall A; Powell SF
J Immunother Cancer; 2019 Dec; 7(1):342. PubMed ID: 31801624
[TBL] [Abstract][Full Text] [Related]
7. Safety and efficacy of AMG 820, an anti-colony-stimulating factor 1 receptor antibody, in combination with pembrolizumab in adults with advanced solid tumors.
Razak AR; Cleary JM; Moreno V; Boyer M; Calvo Aller E; Edenfield W; Tie J; Harvey RD; Rutten A; Shah MA; Olszanski AJ; Jäger D; Lakhani N; Ryan DP; Rasmussen E; Juan G; Wong H; Soman N; Smit MD; Nagorsen D; Papadopoulos KP
J Immunother Cancer; 2020 Oct; 8(2):. PubMed ID: 33046621
[TBL] [Abstract][Full Text] [Related]
8. First-in-human phase I/Ib open-label dose-escalation study of GWN323 (anti-GITR) as a single agent and in combination with spartalizumab (anti-PD-1) in patients with advanced solid tumors and lymphomas.
Piha-Paul SA; Geva R; Tan TJ; Lim DW; Hierro C; Doi T; Rahma O; Lesokhin A; Luke JJ; Otero J; Nardi L; Singh A; Xyrafas A; Chen X; Mataraza J; Bedard PL
J Immunother Cancer; 2021 Aug; 9(8):. PubMed ID: 34389618
[TBL] [Abstract][Full Text] [Related]
9. Potential contribution of tumor-associated slan
Lonardi S; Licini S; Micheletti A; Finotti G; Vermi W; Cassatella MA
J Leukoc Biol; 2018 Mar; 103(3):559-564. PubMed ID: 28951423
[TBL] [Abstract][Full Text] [Related]
10. Phase I study of ABBV-428, a mesothelin-CD40 bispecific, in patients with advanced solid tumors.
Luke JJ; Barlesi F; Chung K; Tolcher AW; Kelly K; Hollebecque A; Le Tourneau C; Subbiah V; Tsai F; Kao S; Cassier PA; Khasraw M; Kindler HL; Fang H; Fan F; Allaire K; Patel M; Ye S; Chao DT; Henner WR; Hayflick JS; McDevitt MA; Fong L
J Immunother Cancer; 2021 Feb; 9(2):. PubMed ID: 33608377
[TBL] [Abstract][Full Text] [Related]
11. Avelumab for metastatic or locally advanced previously treated solid tumours (JAVELIN Solid Tumor): a phase 1a, multicohort, dose-escalation trial.
Heery CR; O'Sullivan-Coyne G; Madan RA; Cordes L; Rajan A; Rauckhorst M; Lamping E; Oyelakin I; Marté JL; Lepone LM; Donahue RN; Grenga I; Cuillerot JM; Neuteboom B; Heydebreck AV; Chin K; Schlom J; Gulley JL
Lancet Oncol; 2017 May; 18(5):587-598. PubMed ID: 28373007
[TBL] [Abstract][Full Text] [Related]
12. PK/PD Mediated Dose Optimization of Emactuzumab, a CSF1R Inhibitor, in Patients With Advanced Solid Tumors and Diffuse-Type Tenosynovial Giant Cell Tumor.
Smart K; Bröske AM; Rüttinger D; Mueller C; Phipps A; Walz AC; Ries C; Baehner M; Cannarile M; Meneses-Lorente G
Clin Pharmacol Ther; 2020 Sep; 108(3):616-624. PubMed ID: 32575160
[TBL] [Abstract][Full Text] [Related]
13. Phase Ib Study of Utomilumab (PF-05082566), a 4-1BB/CD137 Agonist, in Combination with Pembrolizumab (MK-3475) in Patients with Advanced Solid Tumors.
Tolcher AW; Sznol M; Hu-Lieskovan S; Papadopoulos KP; Patnaik A; Rasco DW; Di Gravio D; Huang B; Gambhire D; Chen Y; Thall AD; Pathan N; Schmidt EV; Chow LQM
Clin Cancer Res; 2017 Sep; 23(18):5349-5357. PubMed ID: 28634283
[No Abstract] [Full Text] [Related]
14. A phase 1 study of intravenous mitazalimab, a CD40 agonistic monoclonal antibody, in patients with advanced solid tumors.
Moreno V; Perets R; Peretz-Yablonski T; Fourneau N; Girgis S; Guo Y; Hellemans P; Verona R; Pendás N; Xia Q; Geva R; Calvo E
Invest New Drugs; 2023 Feb; 41(1):93-104. PubMed ID: 36538259
[TBL] [Abstract][Full Text] [Related]
15. Phase I Study of Pembrolizumab (MK-3475; Anti-PD-1 Monoclonal Antibody) in Patients with Advanced Solid Tumors.
Patnaik A; Kang SP; Rasco D; Papadopoulos KP; Elassaiss-Schaap J; Beeram M; Drengler R; Chen C; Smith L; Espino G; Gergich K; Delgado L; Daud A; Lindia JA; Li XN; Pierce RH; Yearley JH; Wu D; Laterza O; Lehnert M; Iannone R; Tolcher AW
Clin Cancer Res; 2015 Oct; 21(19):4286-93. PubMed ID: 25977344
[TBL] [Abstract][Full Text] [Related]
16. First-in-human phase I study of the OX40 agonist GSK3174998 with or without pembrolizumab in patients with selected advanced solid tumors (ENGAGE-1).
Postel-Vinay S; Lam VK; Ros W; Bauer TM; Hansen AR; Cho DC; Stephen Hodi F; Schellens JHM; Litton JK; Aspeslagh S; Autio KA; Opdam FL; McKean M; Somaiah N; Champiat S; Altan M; Spreafico A; Rahma O; Paul EM; Ahlers CM; Zhou H; Struemper H; Gorman SA; Watmuff M; Yablonski KM; Yanamandra N; Chisamore MJ; Schmidt EV; Hoos A; Marabelle A; Weber JS; Heymach JV
J Immunother Cancer; 2023 Mar; 11(3):. PubMed ID: 36927527
[TBL] [Abstract][Full Text] [Related]
17. Long-term clinical activity, safety and patient-reported quality of life for emactuzumab-treated patients with diffuse-type tenosynovial giant-cell tumour.
Cassier PA; Italiano A; Gomez-Roca C; Le Tourneau C; Toulmonde M; D'Angelo SP; Weber K; Loirat D; Jacob W; Jegg AM; Michielin F; Christen R; Watson C; Cannarile M; Klaman I; Abiraj K; Ries CH; Weisser M; Rüttinger D; Blay JY; Delord JP
Eur J Cancer; 2020 Dec; 141():162-170. PubMed ID: 33161240
[TBL] [Abstract][Full Text] [Related]
18. Immune modulation with weekly dosing of an agonist CD40 antibody in a phase I study of patients with advanced solid tumors.
Rüter J; Antonia SJ; Burris HA; Huhn RD; Vonderheide RH
Cancer Biol Ther; 2010 Nov; 10(10):983-93. PubMed ID: 20855968
[TBL] [Abstract][Full Text] [Related]
19. Phase IA/IB study of single-agent tislelizumab, an investigational anti-PD-1 antibody, in solid tumors.
Desai J; Deva S; Lee JS; Lin CC; Yen CJ; Chao Y; Keam B; Jameson M; Hou MM; Kang YK; Markman B; Lu CH; Rau KM; Lee KH; Horvath L; Friedlander M; Hill A; Sandhu S; Barlow P; Wu CY; Zhang Y; Liang L; Wu J; Paton V; Millward M
J Immunother Cancer; 2020 Jun; 8(1):. PubMed ID: 32540858
[TBL] [Abstract][Full Text] [Related]
20. Pamiparib in combination with tislelizumab in patients with advanced solid tumours: results from the dose-escalation stage of a multicentre, open-label, phase 1a/b trial.
Friedlander M; Meniawy T; Markman B; Mileshkin L; Harnett P; Millward M; Lundy J; Freimund A; Norris C; Mu S; Wu J; Paton V; Gao B
Lancet Oncol; 2019 Sep; 20(9):1306-1315. PubMed ID: 31378459
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
